SRPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sarepta Therapeutics Inc (SRPT) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company faces significant financial challenges, declining revenue, and profitability issues, coupled with bearish technical indicators and mixed analyst ratings. While there are some positive catalysts, such as potential siRNA readout and cash flow positivity in 2026, the overall sentiment and financial performance suggest that this stock is not suitable for a long-term beginner investor at this time.
The technical indicators for SRPT are bearish. The MACD is slightly positive but contracting, RSI is neutral at 34.466, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are at S1: 16.879 and R1: 19.048, with the current pre-market price of $17.31 below the pivot level of 17.963, suggesting downward pressure.
Sarepta anticipates being cash flow positive in
Potential positive siRNA readout expected.
Encouraging EMBARK data showing slowing of disease progression.
Hedge funds are heavily selling the stock, with a 12693.27% increase in selling over the last quarter.
CEO Douglas Ingram's announced retirement by the end of 2026 has added uncertainty.
Q4 2025 financials show significant declines in revenue (-32.73% YoY), net income (-359.18% YoY), and EPS (-397.73% YoY).
Sarepta reported a larger-than-expected loss in Q4, with adjusted EPS of -$3.
Analysts have lowered price targets, with Citi maintaining a Sell rating and an $8 price target.
In Q4 2025, Sarepta reported revenue of $442.93 million, down 32.73% YoY. Net income dropped to -$412.23 million, a decline of 359.18% YoY, and EPS fell to -$3.93, down 397.73% YoY. Gross margin also dropped significantly to 9.83%, down 87.68% YoY. Despite having $954 million in cash and investments, the company faces significant profitability challenges.
Analyst sentiment is mixed to negative. Wells Fargo maintains an Overweight rating but lowered the price target to $38. Citi has a Sell rating with an $8 price target, citing downside risks outweighing upside drivers. Baird and Barclays have Neutral and Equal Weight ratings, respectively, with price targets of $20. H.C. Wainwright reiterates a Sell rating with a $5 price target, citing skepticism around EMBARK data reliability.
